Molecular You, a company specializing in personalized medicine, has established a multi-omic blood testing and analysis platform that has shown promising results in identifying stage 1 pancreatic cancer. A case report, published in the journal OMICS and reported on by PR Newswire, “describes the effectiveness of proteomic and metabolomic analysis in identifying pancreatic cancer.”
In the case report, a symptom-free 60-year-old female patient was identified through an assessment as having “a series of blood based biomarkers…in ranges associated with pancreatic cancer.” The lesions were biopsied, revealing stage 1 pancreatic cancer; since it was identified early, she had the lesions surgically removed, preventing the need for further treatment.
The assessment, provided by this new blood testing and analysis platform, was able to identify pancreatic cancer in its early stages. Pancreatic cancer is specifically deadly because it “lacks overt symptoms and is often diagnosed at a late stage when it has become unresectable or metastatic.”
Ash Anwar, lead author of the published report, stated that researchers were “encouraged to see that the post-surgery analysis indicated that the pancreatic cancer biomarkers had returned to normative ranges.” Molecular You’s hope now is that this platform will be applied “longitudinally to a broader population,” according to one of the co-founders, Dr. Pieter Cullis.
